Virpax Pharmaceuticals reduces shareholder meeting quorum threshold to 34%

Virpax Pharmaceuticals, Inc.

Amendment adopted November 27, 2024, lowering quorum from a majority to 34% of voting power.
Change applies to all future shareholder meetings; filed as Exhibit 3.1.
Bylaw modification may ease passage of shareholder proposals and director elections.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Virpax Pharmaceuticals, Inc.: Reduced the quorum requirement for shareholder meetings from a majority of voting power to 34% of voting power (effective 2024-11-27).

Change: bylaw amendment
Effective: 2024-11-27

Exact text from the filing

On November 27, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) amended its Amended and Restated Bylaws (the “Bylaws”) to modify the quorum requirement for shareholder meetings. The amendment reduced the quorum threshold from a majority of the voting power of the Company’s outstanding shares entitled to vote at a meeting to 34% of such voting power.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001731122-24-001899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.